This page shows the latest Cell Design Labs news and features for those working in and with pharma, biotech and healthcare.
Among Gilead's moves is a shift into immuno-oncology via the acquisition of CAR-T specialist Kite Pharma for almost $12bn and smaller player Cell Design Labs, a $3bn agreement
Celgene is in talks with Juno Therapeutics about a possible takeover deal, right after cutting a $7bn deal to buy Impact Labs, according to media reports. ... Gilead followed the Kite deal with a smaller buyout of CAR-T firm Cell Design Labs last month.
Just a few months after shelling out $12bn to buy CAR-T specialist Kite Pharma, Gilead Sciences is boosting its position in the category with a $567m swoop on Cell Design ... for a green light from the FDA for Kymriah (tisagenlecleucel) as a treatment
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
on B-cell tumor cells, including chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (NHL) cells). ... licence. 80. Cell Design Labs/ Kite Pharma. 'On/off switch' technology to regulate activity of engineered CAR T-cells for AML, certain B-cell
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...